| Drug NDC: | 43742-1564 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Kidney Drainage |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Product Type: | Human Prescription Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Solidago Virgaurea, Asparagus Officinalis, Juniperus Communis, Sabal Serrulata, Uva-ursi, Berberis Vulgaris, Equisetum Arvense, Urtica Dioica, Rubia Tinctorum, Staphysagria, Cantharis, Fagus Sylvatica, Flos, Glandula Suprarenalis Suis, Hepar Sulphuris Calcareum, Kidney (suis), Larix Decidua, Flos, Manganum Metallicum, Mimulus Guttatus, Flos, Nitricum Acidum, Rhus Aromatica, Silicea, Ulex Europaeus, Flos, Benzoicum Acidum, Cobaltum Metallicum |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Deseret Biologicals, Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Liquid |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | ARCTOSTAPHYLOS UVA-URSI LEAF - 2 [hp_X]/mL ASPARAGUS - 2 [hp_X]/mL BENZOIC ACID - 12 [hp_X]/mL BERBERIS VULGARIS ROOT BARK - 3 [hp_X]/mL CALCIUM SULFIDE - 8 [hp_X]/mL COBALT - 16 [hp_X]/mL DELPHINIUM STAPHISAGRIA SEED - 6 [hp_X]/mL EQUISETUM ARVENSE TOP - 3 [hp_X]/mL FAGUS SYLVATICA FLOWERING TOP - 8 [hp_X]/mL JUNIPERUS COMMUNIS WHOLE - 2 [hp_X]/mL Load more... LARIX DECIDUA FLOWERING TOP - 8 [hp_X]/mL LYTTA VESICATORIA - 8 [hp_X]/mL MANGANESE - 8 [hp_X]/mL MIMULUS GUTTATUS FLOWERING TOP - 8 [hp_X]/mL NITRIC ACID - 8 [hp_X]/mL PORK KIDNEY - 8 [hp_X]/mL RHUS AROMATICA ROOT BARK - 8 [hp_X]/mL RUBIA TINCTORUM ROOT - 6 [hp_X]/mL SAW PALMETTO - 2 [hp_X]/mL SILICON DIOXIDE - 8 [hp_X]/mL SOLIDAGO VIRGAUREA FLOWERING TOP - 1 [hp_X]/mL SUS SCROFA ADRENAL GLAND - 8 [hp_X]/mL ULEX EUROPAEUS FLOWER - 8 [hp_X]/mL URTICA DIOICA - 3 [hp_X]/mL |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 17 Sep, 2019 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 23 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 31 Dec, 2024 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | Deseret Biologicals, Inc. |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| NUI: | N0000185371 N0000175629 N0000184306 M0000728 M0006342 M0022575 N0000175806 N0000175807 N0000185508 |
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). | |
| UNII: | 3M5V3D1X36 Z1EJP3037Z 8SKN0B0MIM 1TH8Q20J0U 1MBW07J51Q 3G0H8C9362 00543AP1JV 1DP6Y6B65Z 21AF0IHY5U 464910T5N9 Load more... 9UMZ642257 3Q034RO3BT 42Z2K6ZL8P 192426I5JU 411VRN1TV4 X7BCI5P86H Q3H36W0J42 0SVP95L23G J7WWH9M8QS ETJ7Z6XBU4 5405K23S50 398IYQ16YV 398DBS1PXN 710FLW4U46 |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Pharmacologic Class MOA: | Ammonium Ion Binding Activity [MoA] |
| Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`. | |
| Pharmacologic Class EPC: | Non-Standardized Food Allergenic Extract [EPC] Nitrogen Binding Agent [EPC] Standardized Chemical Allergen [EPC] |
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. | |
| Pharmacologic Class PE: | Increased Histamine Release [PE] Cell-mediated Immunity [PE] |
| Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`. | |
| Pharmacologic Class CS: | Allergens [CS] Dietary Proteins [CS] Vegetable Proteins [CS] |
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. | |
| Pharmacologic Class: | Allergens [CS] Ammonium Ion Binding Activity [MoA] Cell-mediated Immunity [PE] Dietary Proteins [CS] Increased Histamine Release [PE] Nitrogen Binding Agent [EPC] Non-Standardized Food Allergenic Extract [EPC] Standardized Chemical Allergen [EPC] Vegetable Proteins [CS] |
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 43742-1564-1 | 60 mL in 1 BOTTLE, DROPPER (43742-1564-1) | 17 Sep, 2019 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.